A key protein, HOXD13, helps melanoma tumors grow and evade the immune system by boosting blood supply and blocking cancer-fighting T cells. Disabling it shrinks tumors and reopens the door for the ...

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses ...

While immunotherapy is the primary driver of skin sensitivity in melanoma care, Wong issued a "public service announcement" ...

As Skin Cancer Awareness Month approaches this May, SkinScan Ireland and Waterford-based GP Dr David Brennan are encouraging people across Ireland to take a more proactive approach to protecting their ...

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit ...

Replimune is laying off 63 staffers days after the second FDA rejection of its melanoma drug. Elsewhere, Revolution raised $2 billion and a regulatory filing revealed details on negotiations between ...

By AARON BEARD, AP Basketball Writer. Famed ESPN broadcaster Dick Vitale is facing another battle with cancer. Related Articles. In Miami, soccer balls are turned into one-of-a-ki ...

Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into ...

A closely watched clinical trial testing a new two-drug combination against metastatic uveal melanoma, the deadliest form of ...

The California-based biotechnology company reports statistically significant results from a clinical trial evaluating its ...

Servier $210 million bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as the drug has hit the mark in a phase 2/3 that could form the basis of regulatory filings later this ...

IDEAYA Biosciences (IDYA) stock jumped 26% after its eye cancer drug combo doubled progression-free survival in a Phase 2/3 trial versus standard care.